Meeting Report - Structured Benefit-Risk Assessment
Structured Benefit-Risk Assessment - Flyer
Why and How do we do benefit-risk assessment in drug regulation: lessons from IMI PROTECT - Prof Deborah Ashby (Imperial College London)
A regulatory perspective of Structured Benefit-Risk - Dr Andrew Thomson (MHRA)
Implementing a structured Benefit Risk Approach - A Company perspective - Rebecca Sudlow (Associate Director, Roche Products Ltd)
IMI PROTECT case study: Structured Benefit-Risk applied to natalizumab - Dr Richard Nixon (Novartis)
An industry case study: Using impactful presentations to support structured Benefit-Risk assessments in practice - Dr Ian Hirsch (AstraZeneca)
AN IMI PROTECT case study: Telithromycin - Dr Christine Hallgreen